LS 216

Drug Profile

LS 216

Alternative Names: PDT research programme - Light Sciences; Photodynamic therapy research programme - Light Sciences; Research programme photodynamic therapy - Light Sciences

Latest Information Update: 24 Mar 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer Light Sciences Corporation; Roswell Park Cancer Institute
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Mar 2005 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 24 Feb 2005 No development reported - Phase-I for Cancer in USA (unspecified route)
  • 12 Jun 2002 Phase-I clinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top